Article Text

FRI0395 Effect of Rituximab on Different Isotypes of Serum Immunoglobulins in Patients with Sle
  1. V. Reddy1,
  2. L. Martinez2,
  3. D. Isenberg1,
  4. G. Cambridge1,
  5. M. Leandro1
  1. 1Bloomsbury Centre for Rheumatology Research, University College London, London, United Kingdom
  2. 2Hospital General Universitario, Gregorio Marañόn, Hospital General Universitario, Gregorio Marañόn, Madrid, Spain


Background The impact of rituximab therapy on different compartments of the immune system may inform as to the possible clinical response and also maintenance of protective immunity. We conducted a retrospective study of serum IgM, IgG and IgA in 57 patients with SLE, following the first cycle of B cell depletion therapy based on rituximab (RTX).

Methods Serum Ig levels (IgA, IgG and IgM) were assessed at baseline (before first infusion of RTX) and at 1, 2, 6, 9 and 12 months after the first cycle of RTX in 57 patients with SLE. Paired t-test and Spearman's rank correlation were used to analyse changes in serum Ig levels and to analyse correlations, respectively.

Results Median baseline serum IgA level was 2.9g/L, which fell by a mean 6% and 10% (p<0.05), at 1 and 2 months after RTX but was similar to baseline at 12 months. IgA levels at baseline showed a positive correlation with IgA levels at all time points (r2≥0.5, p<0.0001 for all).

Median baseline serum IgG level was 13.9g/L, which was significantly reduced (p<0.05) (means of 7%, 11%, 5% and 7% at 1, 2, 6, and 9 after RTX) but levels were similar to baseline at 12 months.

Median baseline serum IgM levels were 1.0g/L, which reduced by means of 13%, 18%, 17%, 29% and 18% at 1, 2, 6, 9, and 12 months respectively (p<0.005 for all).

Serum IgG levels at 12 months either reduced (group1) or increased (group2) from baseline. Interestingly, there was a significant difference in baseline IgG levels between the two groups with a median level of 17.24g/l and 10.7g/l (p=0.0005) for group 1 and 2, respectively. Baseline IgG levels positively correlated with IgG levels at all time-points (r2≥0.6, p<0.005 for all). However, there was no difference in IgG levels at 12 months between the two groups. There was a significant difference in baseline IgM levels between the group of patients who had IgM levels <0.4 at 12 months and those who did not, median levels of 0.48 and 1.05g/l, respectively.

There was no correlation between absolute numbers of CD19+cells at baseline and serum Ig levels or %change in Ig levels at any time-points.

Conclusions Our results reveal a disparity in changes in IgA, IgG and IgM levels following rituximab treatment in SLE. Disease-associated defects in B cell biology particularly accessory cell and T-cell interactions associated with B cell survival and class-switch may, at least in part, account for this disparity.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.4559

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.